Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors for Immunotherapy of Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2033-11-01
Target enrollment:
Participant gender:
Summary
This trial was designed to investigate the safety, response rates and survival outcomes of
patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody
and/or CTLA4 antibody ipilimumab and to compare their differences.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University